Kamada (NASDAQ:KMDA) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Kamada (NASDAQ:KMDA) announced its quarterly earnings data on Wednesday. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.05 by $0.02, Zacks reports. Kamada had a net margin of 9.92% and a return on equity of 6.30%. Kamada updated its FY 2025 guidance to EPS.

Kamada Trading Up 6.0 %

NASDAQ KMDA traded up $0.40 on Wednesday, reaching $7.01. 74,497 shares of the company were exchanged, compared to its average volume of 261,738. Kamada has a fifty-two week low of $4.74 and a fifty-two week high of $9.15. The business’s fifty day moving average price is $7.06 and its 200 day moving average price is $6.13. The stock has a market capitalization of $402.88 million, a P/E ratio of 25.00, a price-to-earnings-growth ratio of 0.97 and a beta of 0.99.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Kamada in a report on Friday, January 10th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.